IBRX vs NBIX · rev $51.2M vs P/E 45, rev $1.77B
Immunitybio Inc (IBRX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
IBRX currently screens at market cap $7.88B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the IBRX and NBIX stock pages for the full models.
Not investment advice.